SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.(2395) News

SHIN NIPPON BIOMEDICAL, First Half Ordinary Profit Decreases by 11%, Jul-Sep Ordinary Profit Decreases by 25%

Presentation Materials for the First Six Months of the Fiscal Year Ending March 31, 2026

Notice Regarding Differences between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2025

Notice Regarding Distribution ofInterim Dividends from Retained Earnings

Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)

SNBL’s Subsidiary, SNLD, Announces Posters to be Presented at the Upcoming International Congress of Parkinson’s Disease and Movement Disorders

SHIN NIPPON BIOMEDICAL, Apr-Jun (1Q) Ordinary Profit Increases by 51%

Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)

Presentation materials on Financial Results for the First Three Months of the Fiscal Year ending March 31, 2026

[Delayed] Corporate Governance Report

Notice Regarding Distribution of Year-end Dividends from Retained Earnings

(Corrections/Corrections of Numerical Data) Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

Presentation Materials for the Fiscal Year Ended March 31, 2025

Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

SHIN NIPPON BIOMEDICAL, 8% Decrease in Ordinary Profit for The Current Fiscal Year

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

SNBL and Tasso, Inc. to Establish Joint Venture in Japan

SNBL’s Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting

SHIN NIPPON BIOMEDICAL, The Current Fiscal Year Ordinary Profit Revised Upward by 10%

Notice Regarding Revisions of the Earnings Forecasts for the Full-Year of the Fiscal Year Ending March 31, 2025